past
centuri
southern
china
epicent
emerg
notabl
infecti
diseas
hong
kong
special
administr
region
hksar
part
southern
china
enjoy
rel
advanc
public
health
infrastructur
intern
connect
often
becam
first
place
emerg
infecti
diseas
discov
dissemin
global
first
exampl
occur
outbreak
plagu
start
canton
guangdong
provinc
china
similar
outbreak
time
acut
communityacquir
atyp
pneumonia
syndrom
occur
guangdong
provinc
late
retrospect
investig
show
sever
case
atyp
pneumonia
record
five
citi
around
guangzhou
period
month
index
case
report
novemb
foshan
citi
km
away
guangzhou
second
case
appear
decemb
chef
heyuan
work
restaur
shenzhen
affect
occup
histori
regular
contact
wildgam
food
anim
transmit
diseas
wife
two
sister
seven
hospit
staff
contact
novemb
februari
case
atyp
pneumonia
report
mainland
china
health
care
worker
link
outbreak
mainland
china
devast
epidem
hksar
rest
world
professor
nephrolog
teach
hospit
guangzhou
china
contact
patient
suffer
unusu
atyp
pneumonia
februari
develop
flulik
symptom
includ
fever
cough
come
hong
kong
arriv
hong
kong
februari
within
day
transmit
infect
peopl
hotel
stay
thorough
investig
patient
fail
reveal
signific
pathogen
one
secondari
case
brotherinlaw
subsequ
becam
infect
underw
open
lung
biopsi
pivot
discoveri
etiolog
diseas
viru
novel
coronaviru
subsequ
call
sever
acut
respiratori
syndrom
sar
coronaviru
infect
contact
hotel
unknowingli
carri
diseas
hospit
hksar
countri
contin
includ
vietnam
canada
singapor
philippin
unit
kingdom
unit
state
back
china
dr
carlo
urbani
physician
station
world
health
organ
offic
hanoi
first
notifi
occurr
diseas
outsid
guangdong
wit
explos
nosocomi
outbreak
hospit
hanoi
index
case
outbreak
one
acquir
infect
februari
hotel
hong
kong
name
atyp
pneumonia
sever
acut
respiratori
syndrom
sar
dr
urbani
descript
diseas
later
succumb
alert
health
author
throughout
world
start
unpreced
collabor
research
laboratori
countri
identifi
etiolog
agent
respons
sar
essenti
acut
communityacquir
nosocomi
pneumonia
respond
convent
antimicrobi
therapi
known
pneumonia
pathogen
case
death
occur
five
contin
world
health
organ
interperson
transmiss
occur
health
care
facil
workplac
home
public
transport
world
health
organ
septemb
may
three
laboratoryassoci
outbreak
report
orellana
laboratoryacquir
case
singapor
taiwan
limit
one
affect
person
wherea
beij
associ
secondari
tertiari
case
world
health
organ
sarscoronaviru
sarscov
like
zoonot
origin
transmit
human
viru
may
circul
among
wild
game
anim
wet
market
southern
china
palm
civet
consid
like
amplif
host
one
like
candid
introduct
human
seropreval
recent
report
civet
anim
market
guangzhou
tu
et
al
initi
human
case
pandem
guangdong
outbreak
epidemiolog
link
game
anim
either
occup
contact
eat
import
rout
interperson
spread
appear
direct
indirect
contact
mucosa
infecti
respiratori
droplet
fomit
world
health
organ
sarscov
detect
respiratori
secret
fece
urin
tear
loon
et
al
nosocomi
transmiss
sar
could
facilit
use
nebul
suction
intub
bronchoscopi
cardiopulmonari
resuscit
sar
patient
gener
larg
number
infecti
droplet
varia
et
al
world
health
organ
christian
et
al
almost
half
sar
case
hong
kong
acquir
infect
within
health
care
facil
institut
leung
et
al
overal
attack
rate
among
hospit
worker
attack
rate
correl
number
sar
patient
admit
lau
et
al
airborn
transmiss
consid
uncommon
given
rel
low
attack
rate
uniqu
form
airborn
transmiss
consid
like
explan
larg
commun
outbreak
privat
hous
estat
neg
pressur
gener
exhaust
fan
coupl
dri
u
trap
sewag
drain
thought
facilit
dissemin
contamin
aerosol
toilet
suggest
plume
contamin
warm
air
along
light
well
carri
wind
block
hous
complex
find
cultur
virus
stool
high
fecal
viral
load
shown
quantit
revers
transcriptas
polymeras
chain
reaction
rtpcr
peiri
et
al
suggest
possibl
fecalor
transmiss
though
prove
conclus
incub
period
estim
day
epidemiolog
control
measur
base
world
health
organ
recommend
maxim
incub
period
day
effect
case
interrupt
transmiss
though
occasion
case
incub
period
found
longer
averag
number
secondari
case
result
singl
case
two
four
world
health
organ
transmiss
result
contact
patient
overt
diseas
rather
asymptomat
mildli
symptomat
case
seropreval
appear
low
normal
individu
health
care
worker
around
asymptomat
famili
contact
quarantin
asymptomat
contact
overal
lee
et
al
peiri
et
al
leung
et
al
zheng
et
al
transmiss
symptomat
patient
tend
occur
fifth
day
onset
diseas
could
explain
rise
viral
load
nasopharyng
secret
peak
around
day
median
time
rtpcr
convert
neg
day
onset
ill
day
discharg
hospit
definit
season
sar
could
document
stage
though
correl
incid
diseas
ambient
temperatur
tan
et
al
also
definit
geograph
cluster
case
upon
retrospect
analysi
geograph
inform
system
famili
coronavirida
consist
group
larg
envelop
positivesens
singlestrand
rna
virus
human
veterinari
import
tabl
largest
genom
rna
virus
sarscov
one
newli
describ
member
genu
coronaviru
ksiazek
et
al
peiri
et
al
primari
viral
isol
achiev
inocul
embryon
monkey
cell
line
vero
cell
subcultur
made
vero
cell
liver
cancer
cell
line
simmon
et
al
colon
carcinoma
cell
line
two
pig
cell
line
poek
ps
hattermann
et
al
contrast
human
coronavirus
sarscov
maintain
cell
cultur
easili
produc
obviou
cytopathet
effect
vero
within
h
sarscov
higher
degre
stabil
environ
compar
known
human
coronavirus
world
health
organ
rabenau
et
al
surviv
least
day
dri
surfac
room
temperatur
day
stool
rabeneu
et
al
electron
microscopi
appear
genom
order
fig
spikeenvelopemembranenucleocapsid
complet
genom
sequenc
similar
member
coronavirida
sarscov
phylogenet
distinct
three
group
known
coronavirus
human
coronavirus
belong
group
van
der
hoek
et
al
human
coronaviru
belong
group
group
consist
avian
coronavirus
phylogenet
analysi
spike
protein
sarscov
isol
hong
kong
outbreak
show
sever
introduct
occur
one
associ
major
outbreak
hong
kong
rest
world
strain
found
earli
stage
outbreak
phylogenet
distinct
major
cluster
closer
guangdong
beij
strain
concur
fact
index
patient
hong
kong
outbreak
guangzhou
medic
doctor
travel
hong
kong
anoth
molecular
epidemiolog
studi
guangdong
outbreak
suggest
diseas
spread
guangdong
hong
kong
rest
world
index
case
chef
handl
game
anim
subsequ
anim
surveil
china
recov
coronaviru
isol
nucleotid
homolog
sarscov
characterist
insert
open
read
frame
orf
also
name
found
anim
isol
snijder
et
al
segment
delet
cross
speci
barrier
human
biolog
effect
delet
remain
elus
number
sarscov
later
stage
epidem
show
larger
delet
around
site
chines
sar
molecular
epidemiolog
consortium
two
independ
molecular
epidemiolog
studi
compar
complet
genom
viru
isol
also
found
evid
strong
posit
select
begin
epidem
follow
purifi
select
indic
amino
acid
substitut
rate
spike
chines
sar
molecular
epidemiolog
consortium
yeh
et
al
song
et
al
studi
suggest
molecular
adapt
viru
occur
interspeci
transmiss
anim
human
small
outbreak
guangzhou
four
human
isol
belong
separ
sublineag
concurr
anim
predominantli
civet
cat
isol
distinct
human
pandem
anim
viru
though
sarscov
distinct
three
exist
group
coronavirus
may
closer
group
cystein
found
domain
spike
protein
spatial
conserv
compar
group
consensu
sequenc
wherea
cystein
residu
conserv
compar
group
snijder
et
al
coronavirus
believ
coevolv
anim
host
possibl
rat
mice
cattl
harbor
group
coronavirus
like
anim
host
sarscov
cat
harbor
group
coronaviru
howev
comparison
phylogenet
tree
known
hostspeci
nucleocapsid
sequenc
coronavirus
done
use
interfer
approach
slide
window
analysi
statist
incongru
indic
multipl
hostspeci
shift
coronavirus
mani
anim
phylogenet
distant
rest
mindel
thu
even
civet
cat
relat
mammal
true
anim
reservoir
rather
mice
rat
would
big
surpris
moreov
civet
cat
relat
mammal
least
serv
major
amplif
mechan
market
southern
china
irrespect
origin
anim
reservoir
control
anim
market
play
pivot
role
epidemiolog
control
sar
genom
evid
anoth
animaltohuman
interspeci
transmiss
event
demonstr
small
outbreak
four
case
earli
guangzhou
song
et
al
metalloproteas
angiotensinconvert
enzym
vero
cell
found
bind
domain
spike
protein
sarscov
li
et
al
cell
transfect
form
multinucl
syncytia
cell
express
spike
express
detect
immunohistochem
stain
enterocyt
pneumocyt
vascular
endotheli
smooth
muscl
cell
ham
et
al
compat
clinic
histopatholog
manifest
sar
includ
diffus
alveolar
damag
colon
mucos
presenc
abund
viral
particl
patient
diarrhea
pulmonari
vascul
thrombosi
lack
viru
infect
cell
line
express
led
rush
find
coreceptor
cell
entri
recent
ctype
lectin
call
lsign
shown
altern
receptor
bind
cell
entri
jeffer
et
al
although
clear
whether
function
receptor
viru
lead
product
viru
replic
murin
bind
less
effici
domain
sarscov
even
less
well
rat
suggest
effici
replic
mous
rat
limit
type
greenough
et
al
pseudotyp
retrovir
vector
carri
e
protein
reveal
protein
necessari
suffici
viru
attach
suscept
cell
simmon
et
al
wang
et
al
viru
entri
occur
via
phdepend
receptormedi
endocyt
pathway
pseudotyp
viru
carri
protein
bind
dcsign
dendrit
cell
without
caus
cell
death
replic
dendrit
cell
may
serv
conduit
infect
suscept
host
cell
case
human
immunodefici
viru
hiv
infect
fragment
amino
acid
domain
local
minim
receptorbind
region
found
truncat
bind
assay
helicas
proteinas
clone
character
chou
et
al
tanner
et
al
yang
et
al
e
envelop
protein
found
form
cationselect
ion
channel
planar
lipid
bilay
wilson
et
al
molecular
model
rnadepend
rna
polymeras
also
publish
provid
clue
function
aspect
enzym
therefor
may
facilit
design
new
antivir
futur
put
target
helicas
put
mrna
methyltransferas
manganesedepend
endoribonulceas
nsp
bhardwaj
et
al
singlestrand
rna
bind
protein
investig
intens
bioinformat
crystal
structur
studi
campanacci
et
al
von
grotthuss
et
al
egloff
et
al
nomenclatur
nonstructur
protein
summar
tabl
fulllength
cdna
viral
genom
shown
caus
lytic
infect
cell
line
good
viral
titer
antigen
express
yount
et
al
would
provid
tool
studi
function
mani
nonstructur
protein
revers
genet
typic
manifest
sar
twothird
case
viral
pneumonia
rapid
respiratori
deterior
world
health
organ
present
symptom
gener
fever
chill
myalgia
malais
nonproduct
cough
rhinorrhea
sore
throat
less
frequent
seen
clinic
deterior
often
occur
week
onset
ill
may
accompani
wateri
diarrhea
physic
sign
chest
examin
mild
compar
radiograph
abnorm
chest
radiograph
may
show
groundglass
opac
focal
consolid
typic
peripheri
often
subpleur
region
lower
zone
progress
involv
lung
may
occur
may
shift
radiograph
shadow
pneumomediastinum
without
previou
use
posit
pressur
ventil
diarrhea
commonest
extrapulmonari
manifest
cheng
et
al
follow
hepat
dysfunct
chau
et
al
dizzi
may
relat
diastol
cardiac
impair
abnorm
urinalysi
petechia
myositi
wang
et
al
epilept
fit
lau
et
al
neuromuscular
abnorm
like
relat
criticalil
polyneuropathi
andor
myopathi
elderli
patient
may
mere
admit
fall
fractur
absenc
fever
symptom
sign
suggest
sar
chow
et
al
infect
children
appear
milder
adult
wherea
pregnant
women
infect
sar
could
pose
signific
manag
problem
carri
high
casefat
rate
although
transmiss
neonat
document
yudin
et
al
viral
replic
differ
site
appear
account
variou
clinic
laboratori
abnorm
sar
farca
et
al
nasopharyng
serum
viral
load
associ
oxygen
desatur
mechan
ventil
mortal
stool
viral
load
diarrhea
urin
viral
load
abnorm
urinalysi
peripher
lymphocytopenia
common
without
thrombocytopenia
increas
ddimer
activ
partial
thromboplastin
time
elev
hepat
parenchym
enzym
muscl
enzym
lactat
dehydrogenas
may
seen
patient
deterior
requir
mechan
ventil
overal
mortal
death
usual
relat
respiratori
failur
concurr
sepsi
deterior
underli
medic
ill
age
presenc
comorbid
cardiac
problem
diabet
mellitu
increas
lactat
dehydrogenas
level
hypouricemia
acut
renal
failur
extens
pulmonari
radiolog
involv
present
high
neutrophil
count
time
admiss
poor
prognost
indic
survivor
residu
groundglass
opacif
followup
chest
xray
probabl
due
fibrosi
radiolog
abnorm
improv
time
advanc
age
previou
intens
care
unit
admiss
mechan
ventil
altern
treatment
higher
peak
lactat
dehydrogenas
peak
radiograph
involv
treatment
posit
correl
overal
reticul
total
parenchym
involv
month
restrict
lung
function
abnorm
attribut
residu
lung
fibrosi
muscl
weak
commonli
seen
convalesc
phase
incid
least
studi
ong
et
al
depress
posttraumat
stress
disord
especi
common
patient
affect
famili
member
among
health
care
worker
psychosi
could
relat
use
corticosteroid
underli
predisposit
result
treatment
corticosteroid
patient
may
biochem
evid
adren
insuffici
recoveri
also
cumul
doserel
risk
osteonecrosi
rang
griffith
al
pathognomon
sign
symptom
sar
etiolog
diagnosi
differenti
caus
atyp
pneumonia
made
laboratori
confirm
posit
viral
cultur
respiratori
fecal
occasion
urin
specimen
fourfold
rise
neutral
antibodi
titer
serum
taken
admiss
day
afterward
definit
evid
infect
method
realtim
quantit
rtpcr
nasopharyng
aspir
practic
aid
clinic
diagnosi
achiev
sensit
good
specif
collect
within
first
day
ill
antibodi
test
indirect
immunofluoresc
antibodi
test
commonli
perform
neutral
antibodi
test
sinc
former
involv
manipul
infecti
viru
therefor
carri
less
biohazard
risk
recombin
nucleocapsid
enzym
immunoassay
eia
use
rapid
screen
test
possess
high
sensit
earli
day
onset
ill
che
eia
nucleocapsid
antigen
sarscov
may
occasion
yield
falseposit
result
may
requir
confirm
western
blot
spike
polypepetid
sarscov
new
immunofluoresc
assay
use
recombin
nucleocapsidspik
fusion
protein
antigen
describ
viral
load
determin
nasopharyng
specimen
serum
present
might
clinic
valu
import
prognost
factor
cheng
et
al
three
laboratori
outbreak
sar
prompt
use
pseudotyp
virus
research
neutral
antibodi
test
acut
diffus
alveolar
damag
airspac
edema
promin
featur
patient
die
tenth
day
onset
ill
frank
et
al
nichol
et
al
hyalin
membran
interstiti
edema
interstiti
infiltr
inflammatori
cell
bronchiolar
injuri
loss
cilia
bronchiolar
epitheli
denud
focal
deposit
fibrin
expos
basement
membran
observ
featur
patient
die
tenth
day
ill
exhibit
mixtur
acut
chang
organ
phase
diffus
alveolar
damag
interstiti
airspac
fibroblast
prolifer
type
ii
pneumocyt
hyperplasia
squamou
metaplasia
bronchial
epithelium
alveolar
space
contain
combin
macrophag
desquam
pneumocyt
multinucl
cell
hemophagocytosi
alveolar
exud
thrombosi
venul
note
case
pulmonari
complic
might
includ
secondari
bacteri
bronchopneumonia
invas
aspergillosi
wang
et
al
system
vascul
involv
wall
small
vein
edema
fibrinoid
necrosi
infiltr
monocyt
lymphocyt
plasma
cell
note
one
report
tissu
destruct
inflammatori
process
associ
viral
infect
note
organ
tissu
viral
particl
detect
situ
hybrid
pneumocyt
enterocyt
small
intestin
howev
inflamm
cellular
apoptosi
microvilli
atrophi
found
intestin
mucosa
account
wateri
diarrhea
immunohistochem
stain
show
presenc
viral
protein
pneumocyt
occasion
macrophag
necrosi
atrophi
lymphoid
tissu
lymph
node
white
pulp
spleen
commonli
observ
extrapulmonari
patholog
flow
cytometri
examin
peripher
blood
time
admiss
use
steroid
shown
decreas
level
dendrit
cell
subset
natur
killer
cell
lymphocyt
b
lymphocyt
cui
et
al
li
et
al
zhang
et
al
studi
three
sar
patient
suggest
selflimit
abort
infect
peripher
blood
mononuclear
cell
occur
evid
presenc
minusrna
replic
intermedi
viru
initi
week
ill
studi
cytokin
profil
sar
patient
show
signific
elev
plasma
chemokin
interleukin
il
monocyt
chemotact
protein
interferongammainduc
protein
cytokin
interferongamma
inflammatori
cytokin
induc
intens
inflammatori
respons
jone
et
al
huang
et
al
jiang
et
al
may
account
recruit
accumul
alveolar
macrophag
polymorph
activ
cellmedi
immun
stimul
natur
killer
cytotox
lymphocyt
contrast
sarscov
appear
evad
trigger
alpha
beta
interferon
respons
human
macrophag
lack
antivir
innat
immun
respons
may
permit
uncontrol
viral
replic
progress
increas
viral
load
continu
second
week
ill
appear
adapt
immun
respons
bring
viru
replic
control
moreov
compar
transcriptom
microarray
analysi
show
sarscov
rather
markedli
upregul
gene
associ
apoptosi
inflamm
stress
respons
procoagul
earli
phase
infect
human
liver
cancer
cell
line
find
help
explain
clinic
sever
sar
relat
high
viral
load
week
ill
intens
inflammatori
respons
evid
serum
cytokin
profil
histopatholog
gener
specif
serum
antibodi
indirect
immunofluoresc
neutral
test
start
appear
around
day
plateau
around
second
month
maintain
month
igm
igg
appear
around
time
former
detect
month
serum
test
recombin
nucleocapsid
eia
detect
antibodi
earli
fifth
day
onset
symptom
studi
suggest
possibl
associ
hlab
suscept
sever
sar
among
chines
popul
taiwan
among
hong
kong
chines
popul
similar
associ
found
hlab
koch
postul
sarscov
caus
agent
sar
fulfil
primat
model
use
cynomolgu
macaqu
macaca
fasciculari
demonstr
clinic
patholog
featur
similar
found
human
contrari
african
green
monkey
cercopithecu
aethiop
develop
signific
lung
patholog
inocul
sarscov
lack
consist
primat
anim
model
rhesu
cynomolgu
african
green
monkey
experiment
sar
diseas
note
recent
studi
ferret
mustela
furo
domest
cat
feli
domesticu
also
suscept
infect
sarscov
martina
et
al
cat
remain
asymptomat
infect
ferret
die
diseas
balbc
mice
demonstr
asymptomat
infect
lung
nasal
turbin
intranas
inocul
contrast
golden
syrian
hamster
high
level
viral
replic
seen
recent
palm
civet
paguma
larvata
shown
suscept
symptomat
infect
sar
coronaviru
without
signatur
sequenc
experiment
infect
sarscov
also
demonstr
pig
weingartl
et
al
differ
sarscov
isol
use
group
therefor
uncertain
whether
one
particular
anim
would
better
other
model
sarscov
howev
divers
rang
mammalian
speci
suscept
experiment
infect
sarscov
caus
concern
inde
first
report
anim
sar
coronaviru
show
chines
ferret
badger
melogal
moschata
raccoon
dog
nyctereut
procyonoid
could
also
infect
sarscov
clinic
manag
sar
reli
respiratori
support
intens
care
random
clinic
trial
valu
potenti
antivir
agent
oxygen
deliveri
lowflow
nasal
cannula
rather
highflow
facemask
use
minim
risk
nosocomi
airborn
spread
mode
noninvas
ventil
continu
posit
airway
pressur
cpap
bilevel
posit
airway
pressur
bipap
perform
negativepressur
isol
room
adequ
person
protect
equip
health
care
worker
cheung
et
al
broadspectrum
antimicrobi
coverag
communityacquir
pneumonia
given
present
pend
virolog
confirm
nosocomi
infect
import
complic
prolong
intub
hospit
use
corticosteroid
associ
viral
load
clinic
outcom
rais
possibl
effect
suppress
viral
replic
may
benefici
vitro
suscept
test
result
conflict
may
partli
due
use
differ
assay
condit
endpoint
determin
contradictori
result
vitro
activ
interferon
cinatl
et
al
hensley
et
al
tan
et
al
interferon
stroher
et
al
tan
et
al
antivir
effect
interferon
appear
mediat
mechan
mxa
protein
spiegel
et
al
overal
appear
interferon
interferon
interferon
leukocyt
interferon
activ
could
consid
studi
clinic
trial
spiegel
et
al
zheng
et
al
report
note
sensit
ribavirin
concentr
mgl
relat
cellular
toxic
wherea
anoth
report
cytotox
concentr
ribavirin
exce
mgl
cinatl
et
al
interest
see
group
report
good
activ
ribavirin
human
anim
cell
line
despit
initi
report
lack
activ
ribavirin
vero
cell
glycyrrhizin
baicalin
cinatl
et
al
reserpin
niclosamid
aurintricarboxyl
acid
chloroquin
keyaert
et
al
proteas
inhibitor
especi
nelfinavir
xiong
et
al
yamamoto
et
al
found
antivir
acit
sarscov
also
interest
find
organ
nitric
oxid
donor
snitronacetylpenicillamin
also
appear
inhibitori
activ
sarscov
akerstrom
et
al
provid
rational
use
nitric
oxid
inhal
rescu
therapi
sar
good
vitro
antivir
activ
also
observ
analogu
towler
et
al
helicas
inhibitor
nucleosid
analogu
screen
combinatori
chemic
librari
synergist
activ
seen
combin
interferon
compound
ribavirin
cinatl
et
al
sarscov
spike
protein
use
mechan
similar
class
fusion
protein
mediat
membran
fusion
henc
cell
entri
bosch
et
al
antivir
peptid
design
inhibit
claw
mechan
spike
protein
might
use
vitro
kliger
levanon
liu
et
al
peptid
deriv
heptad
repeat
region
sarscov
protein
abl
block
viral
infect
yuan
et
al
zhu
et
al
sirna
design
sequencespecif
degrad
viral
rna
gener
transcript
demonstr
activ
reduc
cytopath
effect
viral
replic
viral
protein
express
cell
line
zhang
et
al
lu
et
al
wang
et
al
zhang
et
al
zheng
et
al
screen
combinatori
chemic
librari
identifi
inhibitor
proteas
helicas
spikemedi
cell
entri
immunodul
empir
use
treatment
sar
initi
epidem
includ
corticosteroid
intraven
immunoglobulin
pentaglobin
thymosin
thalidomid
antitumor
necrosi
factor
corticosteroid
previous
use
manag
viral
pneumonia
due
varicellazost
viru
influenza
viru
virus
greav
et
al
ahm
et
al
mortal
first
two
infect
appear
lower
corticosteroid
support
treatment
alon
highdos
hydrocortison
reduc
express
proinflammatori
chemokin
cxcl
coronavirusinfect
cell
line
howev
unless
effect
antivir
agent
avail
earli
use
high
dose
corticosteroid
prolong
period
could
detriment
may
increas
risk
nosocomi
infect
avasuclar
bone
necrosi
one
studi
shown
earli
use
corticosteroid
actual
increas
plasma
viral
load
pegyl
interferon
shown
use
prophylaxi
reduc
respiratori
viral
shed
lung
patholog
use
earli
treatment
monkey
model
combin
steroid
either
recombin
consensu
loutfi
et
al
proteas
inhibitor
ribavirin
improv
outcom
two
differ
treatment
trial
use
histor
control
chan
et
al
passiv
immun
use
convalesc
plasma
high
titer
neutral
antibodi
use
sar
patient
continu
deterior
signific
advers
reaction
note
although
appear
benefici
either
current
hyperimmun
globulin
produc
convalesc
patient
plasma
equin
plasma
immun
inactiv
sarscov
avail
prophylact
trial
human
human
monoclon
produc
singlechain
variabl
region
fragment
domain
two
nonimmun
human
antibodi
librari
also
produc
sui
et
al
one
singlechain
variabl
region
fragment
block
receptor
interact
bind
domain
murin
model
asymptomat
sar
infect
passiv
immun
high
titer
neutral
antibodi
prevent
viru
replic
lung
effect
nasal
turbin
similarli
passiv
immun
mice
ferret
human
monoclon
antibodi
effect
prevent
develop
lung
patholog
less
effect
reduc
pharyng
excret
current
random
placebo
control
trial
role
antibodi
therapi
preor
postexposur
prophylaxi
atrisk
group
sar
epidem
retrospect
analysi
outcom
human
studi
use
sar
convalesc
plasma
suggest
passiv
immun
major
side
effect
perhap
clinic
benefit
soo
et
al
appear
antibodi
respons
viral
spike
antigen
key
factor
protect
infect
similar
find
found
murin
model
use
either
intramuscular
intranas
administr
highli
attenu
modifi
vaccinia
viru
ankara
carri
spike
protein
bisht
et
al
mucos
immun
african
green
monkey
recombin
attenu
parainfluenza
virussarscov
spike
protein
chimer
viru
result
good
neutral
antibodi
respons
protect
viral
replic
upper
lower
respiratori
tract
live
sarscov
challeng
approach
activ
immun
involv
use
adenovir
vector
carri
n
protein
rhesu
macaqu
inactiv
whole
viru
vaccin
mice
protein
fragment
rabbit
mice
zhang
et
al
dna
vaccin
nucleocapsid
gene
mice
zhu
et
al
adenovir
vector
carri
domain
membran
nucleoprotein
dna
vaccin
link
nucleocapsid
protein
calreticulin
kim
et
al
plasmid
dna
vaccin
carri
spike
protein
encod
human
codon
highli
protect
mous
model
furthermor
tcell
deplet
specif
monoclon
antibodi
alon
combin
affect
protect
immun
confirm
adopt
tcell
transfer
donor
cell
alon
inhibit
pulmonari
viral
replic
recipi
mice
wherea
passiv
transfer
purifi
igg
immun
mice
achiev
similar
protect
summari
tabl
vaccin
base
spike
protein
appear
capabl
induc
neutral
antibodi
respons
carri
nucleoprotein
induc
nucleoproteinspecif
cellmedi
immun
rel
import
system
mucos
immun
term
neutral
antibodi
cytotox
lymphocyt
respons
spike
nucleocapsid
target
term
recoveri
sar
unknown
nevertheless
neutral
antibodi
spike
appear
crucial
prophylact
immun
liveattenu
viru
unlik
use
owe
concern
revers
virul
recombin
wild
strain
form
new
wild
type
inactiv
sarscov
like
candid
clinic
trial
recombin
protein
express
mammalian
cell
also
use
induc
good
neutral
antibodi
respons
irrespect
approach
immun
one
bear
mind
phenomenon
immun
enhanc
diseas
occur
felin
periton
coronaviru
infect
sarscov
vaccin
may
inde
lead
increas
derang
liver
function
challeng
ferret
previous
vaccin
weingartl
et
al
atyp
sever
form
diseas
occur
use
inactiv
measl
respiratori
syncyti
viru
vaccin
econom
viabil
sar
vaccin
depend
much
risk
anoth
sar
epidem
futur
major
antigen
variat
might
appear
infect
control
sar
paramount
import
within
health
care
facil
given
rel
stabil
sarscov
environ
absenc
protect
immun
gener
popul
lack
effect
antivir
vaccin
triag
suspect
case
earli
case
detect
prompt
isol
suspect
case
princip
measur
nosocomi
transmiss
respiratori
droplet
contact
precaut
effect
circumst
airborn
precaut
must
consid
situat
droplet
nuclei
like
gener
strict
hand
hygien
prefer
patrol
nurs
overse
gown
degown
procedur
sar
ward
critic
import
contact
trace
quarantin
contact
prevent
commun
spread
temperatur
check
border
health
declar
travel
public
educ
effect
risk
commun
public
media
use
pandem
effect
control
sar
laboratori
must
strictli
compli
world
health
organ
standard
live
virus
cultiv
handl
accredit
biosafeti
level
laboratori
daili
check
temperatur
report
sick
part
monitor
protocol
laboratori
worker
handl
live
virus
although
screen
intern
border
airport
wide
practic
epidem
valu
screen
recent
question
st
john
et
al
nevertheless
travel
epidem
may
less
vigil
prevent
measur
diseas
remain
import
target
prevent
crossbord
spread
infect
lau
et
al
